271 related articles for article (PubMed ID: 36621179)
1. Design, synthesis and biological evaluation of KRAS
Zhang X; Zhao T; Sun M; Li P; Lai M; Xie L; Chen J; Ding J; Xie H; Zhou J; Zhang H
Bioorg Med Chem; 2023 Jan; 78():117153. PubMed ID: 36621179
[TBL] [Abstract][Full Text] [Related]
2. Discovery of highly potent and selective KRAS
Yang N; Fan Z; Sun S; Hu X; Mao Y; Jia C; Cai X; Xu T; Li B; Li Y; Han L; Wei T; Qian X; Qin W; Li P; Zheng Z; Li S
Eur J Med Chem; 2023 Dec; 261():115857. PubMed ID: 37852032
[TBL] [Abstract][Full Text] [Related]
3. Efficient targeted oncogenic KRAS
Yang F; Wen Y; Wang C; Zhou Y; Zhou Y; Zhang ZM; Liu T; Lu X
Eur J Med Chem; 2022 Feb; 230():114088. PubMed ID: 35007863
[TBL] [Abstract][Full Text] [Related]
4. Exploring Targeted Degradation Strategy for Oncogenic KRAS
Zeng M; Xiong Y; Safaee N; Nowak RP; Donovan KA; Yuan CJ; Nabet B; Gero TW; Feru F; Li L; Gondi S; Ombelets LJ; Quan C; Jänne PA; Kostic M; Scott DA; Westover KD; Fischer ES; Gray NS
Cell Chem Biol; 2020 Jan; 27(1):19-31.e6. PubMed ID: 31883964
[TBL] [Abstract][Full Text] [Related]
5. Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity.
Li L; Wu Y; Yang Z; Xu C; Zhao H; Liu J; Chen J; Chen J
Bioorg Chem; 2021 Dec; 117():105447. PubMed ID: 34715575
[TBL] [Abstract][Full Text] [Related]
6. Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras.
Hamilton G; Stickler S; Rath B
Curr Pharm Des; 2023; 29(22):1741-1746. PubMed ID: 37073657
[TBL] [Abstract][Full Text] [Related]
7. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
Zhu H; Wang J; Zhang Q; Pan X; Zhang J
Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel PROTACs based on multi-targeted angiogenesis inhibitors.
Si R; Hai P; Zheng Y; Liu N; Wang J; Zhang Q; Li Y; Pan X; Zhang J
Bioorg Med Chem Lett; 2023 May; 87():129275. PubMed ID: 37030566
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS
Zhou C; Fan Z; Gu Y; Ge Z; Tao Z; Cui R; Li Y; Zhou G; Huo R; Gao M; Wang D; He W; Zheng M; Zhang S; Xu T
J Med Chem; 2024 Jan; 67(2):1147-1167. PubMed ID: 38197882
[TBL] [Abstract][Full Text] [Related]
10. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
11. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
12. The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells.
Kurimchak AM; Herrera-Montávez C; Montserrat-Sangrà S; Araiza-Olivera D; Hu J; Neumann-Domer R; Kuruvilla M; Bellacosa A; Testa JR; Jin J; Duncan JS
Sci Signal; 2022 Aug; 15(749):eabn2707. PubMed ID: 36041010
[TBL] [Abstract][Full Text] [Related]
13. Discovery of LHF418 as a new potent SOS1 PROTAC degrader.
Li H; Chai M; Chen Y; Zhou F; Ren X; Xu J; Wang J; Wang Z; Huang W
Bioorg Med Chem; 2024 Apr; 103():117661. PubMed ID: 38489998
[TBL] [Abstract][Full Text] [Related]
14. Targeted Degradation of Oncogenic KRAS
Bond MJ; Chu L; Nalawansha DA; Li K; Crews CM
ACS Cent Sci; 2020 Aug; 6(8):1367-1375. PubMed ID: 32875077
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
16. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond.
Nagasaka M; Potugari B; Nguyen A; Sukari A; Azmi AS; Ou SI
Cancer Treat Rev; 2021 Dec; 101():102309. PubMed ID: 34715449
[TBL] [Abstract][Full Text] [Related]
17. Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells.
Yu X; Xu J; Cahuzac KM; Xie L; Shen Y; Chen X; Liu J; Parsons RE; Jin J
J Med Chem; 2022 Oct; 65(20):14237-14260. PubMed ID: 36197750
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Small Molecule PROTACs for the Treatment of Cancer.
Li W; Elhassan RM; Hou X; Fang H
Curr Med Chem; 2021; 28(24):4893-4909. PubMed ID: 33208057
[TBL] [Abstract][Full Text] [Related]
19. FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer.
Liu J; Xue L; Xu X; Luo J; Zhang S
Exp Cell Res; 2021 Nov; 408(2):112868. PubMed ID: 34648846
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido[2,3-d]pyrimidin-7-one-based SOS1 inhibitor.
Wang K; Zhou Z; Ma X; Xu J; Xu W; Zhou G; Zhou C; Li H; Zheng M; Zhang S; Xu T
Bioorg Med Chem Lett; 2024 Jul; 107():129780. PubMed ID: 38714262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
